Saredutant

Generic Name
Saredutant
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C31H35Cl2N3O2
CAS Number
142001-63-6
Unique Ingredient Identifier
720U2QK8I5
Background

Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.

Indication

Investigated for use/treatment in depression and anxiety disorders.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression

Phase 3
Completed
Conditions
Depressive Disorder
First Posted Date
2007-01-31
Last Posted Date
2012-02-17
Lead Sponsor
Sanofi
Target Recruit Count
125
Registration Number
NCT00429260
Locations
🇺🇸

Administrative Office, Malvern, Pennsylvania, United States

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

First Posted Date
2006-12-29
Last Posted Date
2016-05-24
Lead Sponsor
Sanofi
Target Recruit Count
365
Registration Number
NCT00417118
Locations
🇹🇷

Sanofi-Aventis Administrative Office, Istanbul, Turkey

A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

Phase 3
Completed
Conditions
Anxiety
First Posted Date
2006-10-20
Last Posted Date
2011-04-06
Lead Sponsor
Sanofi
Target Recruit Count
366
Registration Number
NCT00390650
Locations
🇨🇦

Sanofi-Aventis, Laval, Canada

An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder

Phase 3
Completed
Conditions
Generalized Anxiety
Interventions
Drug: Saredutant
Drug: Placebo
First Posted Date
2006-10-20
Last Posted Date
2016-05-24
Lead Sponsor
Sanofi
Target Recruit Count
428
Registration Number
NCT00390533
Locations
🇦🇺

Sanofi-Aventis Administrative Office, Macquarie Park, Australia

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy